Kornimate/medical-research-clean huggingface dataset:
renal graft function after treatment with erythropoietin (epo)

Conditions: Ischemia

Summary: background : numerous studies have outlined the cellular pleiotropic effects of erythropoietin (epo) and their role in the prevention of ischemic-reperfusion lesion such as after acute ischemic injury of the brain or the heart. however, most of these studies were carried out in animal models and no definitive proof exists today to demonstrate that epo has similar beneficial effects in human pathology. purpose : the aim of the study is to demonstrate that in humans, epo can protect against ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.

abstract : since the discovery that epo and its receptor are expressed in various tissues, numerous studies have demonstrated that epo is not only involved in erythropoiesis but also exerts pleiotropic effects on cells. among these, one of the most exciting is its role in the prevention of ischemic-reperfusion lesions such as after acute ischemic injury of the brain or the heart. however, most of these studies were carried out in animal models and no definitive proof exists today to demonstrate that epo has similar beneficial effects in human pathology. kidney transplantation is one ischemic situation where epo pleiotropic effects could be of great interest since ischemic-reperfusion lesions have been involved in delayed graft function and impaired graft outcomes. the aim of this prospective randomized double blind study is to assess the effect of 100 000 ui of béta-epoiétin on kidney graft function, given to the deceased donor one hour before the retreaval of the organ. recipients will be followed for three months in order to evaluate kidney function (glomerular filtration rate) and the number of acute rejection episodes to determine whether beta-epoietin could modify the immunogenicity of the graft.

Eligibility criteria:
inclusion criteria: * donor: * cadaveric organ donor, * age ≥ 18 years, * mono-organ (kidney) retrieval, * retrieval done in the centres of limoges, bordeaux, toulouse, angers, brest, nantes, poitiers, rennes, tours, * hematocrit ≤ 45%. * recipient: * age ≥ 18 years, * on the waiting list for a kidney graft. exclusion criteria: * living donors, * age under 18 years, * multi-organ retrieval, * donor hematocrit above 45%

Keywords: high dose of epo transplant kidney cadaveric organ donor mono-organ (kidney) retrieval patient kidney graft
integrative treatment methods in covid-19

Conditions: COVID-19; Patient Experience; Health Attitude

Summary: this study was conducted to examine the use of integrative treatment methods by individuals undergoing covid-19. in this study, which was designed in the qualitative and phenomenological type, the criterion sampling method was used and 12 people were included in the sample.

this study was a qualitative type of phenomenological study conducted to examine the use of integrative treatment methods by individuals undergoing covid-19. the study was completed with 12 people. the data were collected between july and october 2021. the interviews lasted for an average of 25-30 minutes. the data collected with the semi-structured interview form were analyzed by descriptive content analysis method after the interviews were over.

Eligibility criteria:
inclusion criteria: * individuals who underwent covid-19 and used any of the integrative treatment methods * agreed to participate in the study constituted the sample group. exclusion criteria: -

Keywords: covid-19 patient experince integrative treatment qualitative study health promotion model
a prospective study on clinical effectiveness after smile versus smile xtra in myopia

Conditions: Myopia

Summary: to evaluate the clinical efficacy and refractive stability of smile xtra compared to smile in patients with myopia


Eligibility criteria:
inclusion criteria: 1. age between 18 and 50 years. 2. high myopia with a manifest refraction spherical equivalent (mrse) - 6.00d～-10.00d and refractive changes within ± 0.50d in the past two years; 3. best corrected distance visual acuity (cdva) ≥ 20/25. 4. preoperative refractive status is stable (myopia progression not exceeding 0.50d per year for at least 2 years). 5. predicted residual stromal thickness (rst) ≥ 250μm after lenticule removal. 6.soft contact lenses discontinued for at least 1 week, rigid contact lenses for at least 3 weeks, and orthokeratology lenses for at least 3 months. exclusion criteria: 1. the presence of other eye diseases: keratoconus or suspected keratoconus, active keratoconjunctivitis, severe dry eye, glaucoma, retinal diseases such as retinal tears or macular degeneration, etc., 2. the presence of significant corneal scarring or cataracts affects observation. 3. systemic diseases such as active systemic inflammation, connective tissue diseases, other conditions that prevent
effects of pain neuroscience education on pain attitudes and beliefs in physiotherapy assistant students

Conditions: Musculoskeletal Pain

Summary: the goal of this educational trial is to learn whether pain neuroscience education (pne) improves pain-related attitudes and beliefs in physiotherapy assistant (pta) students in turkey compared to traditional pain education. the main questions this study aims to answer are: does a single-session pne-based education improve students' beliefs about the relationship between pain and disability? does it reduce reliance on biomedical (organic) pain beliefs compared to traditional pain education? in this study, researchers will compare pne-based education to traditional pain education, both delivered through 70-minute lectures. participants were randomly assigned to either the pne group or the traditional education group, attended a one time 70-minute classroom lecture, completed questionnaires at three time points: before the session, immediately after, and 3 months later. the main tools used will be the health care providers' pain attitudes and impairment relationship scale (hc-pairs) and the pain beliefs questionnaire (pbq), which includes organic and psychological subscales. this study aims to support the integration of contemporary pain neuroscience content into physiotherapy assistant curricula to enhance biopsychosocial understanding at an early stage of professional education.

in turkey, research on the impact of pain neuroscience education (pne) on the knowledge, beliefs, and attitudes of undergraduate physiotherapy students remains scarce. moreover, there appears to be no study that directly contrasts traditional pain education with a pne-based approach that conceptualizes pain as an outcome-driven process, enriched with metaphors and storytelling. existing literature suggests that physiotherapy assistant programs often provide limited exposure to neuroscience content, which may contribute to the lack of significant improvements in students' understanding and attitudes toward pain following pne. against this background, the current study was developed to explore how a metaphor-supported, case-based pne intervention influences the pain-related knowledge and beliefs of physiotherapy assistant students. to the best of our knowledge, no prior study in turkey has systematically evaluated the effects of pne within this specific student group. therefore, a randomized controlled trial was designed to compare the outcomes of traditional structural pain education and a neuroscience-based educational program on pain-related beliefs and attitudes among physiotherapy assistant students.

Eligibility criteria:
inclusion criteria: * students were eligible to participate if they were undergraduate physiotherapy assistant students enrolled at the vocational school of health services. exclusion criteria: * individuals were excluded if they had previously received in-depth teaching on pain neurophysiology or traditional pain education.
study of the use of misoprostol to decrease bleeding during a myomectomy

Conditions: Hemorrhage

Summary: this study was done to determine if the use of a combination of preoperative rectal misoprostol 400µg used with intraoperative perivascular vasopressin is better than perivascular vasopressin used alone to decrease bleeding at myomectomy.

a myomectomy is a fertility sparing procedure in which fibroids are removed from the uterus. this procedure can be associated with significant blood loss which can result in significant morbidity and mortality. the drug misoprostol which has been been use in the treatment of postpartum hemorrhage was given to subset of patients who were scheduled to undergo elective myomectomy at the university hospital of the west indies and from the private practice of the participating doctors who were invited to participate in the study. patients were randomized to receive or not to receive pre-operative rectal misoprostol 400µg, 60 minutes before surgery. twenty five patients received misoprostol and twenty patients did not.

Eligibility criteria:
inclusion criteria: * patients with symptomatic fibroids who desire future fertility and or who wish to maintain their uterus. exclusion criteria: * patients who have had previous myomectomy or previous pelvic surgery. * patients who are severely anemic or who have significant medical conditions such as cardiac or pulmonary disease. * patients who refuse to participate or give consent to the procedures. patients with a known allergy to any of the study drugs.

Keywords: myomectomy
"early tips" versus glue obliteration to prevent rebleeding from gastric varices

Conditions: Bleeding Gastric Varices; Cirrhosis

Summary: the primary objective of the study is to demonstrate the superiority of an "early tips" strategy over standard treatment by glue obliteration (g0) in preventing bleeding recurrence or death at one year after a non gov1 gastric variceal bleeding in cirrhotic patients initially treated by go.


Eligibility criteria:
inclusion criteria: * cirrhotic patients: the diagnosis of liver cirrhosis will be based on previous needle liver biopsy or on the combination of clinical, biochemical, and radiological findings. if biopsy findings are unavailable and in case of non-complicated cirrhosis, non-invasive markers will be used. * variceal bleeding at endoscopy from gastroesophageal gastric varices type 2 or isolated gastric varices type 1 or 2 (sarin classification) according to the following criteria: endoscopic signs of an active spurting or oozing from gastric varices (gv); adherent blood clots, white nipple signs, or erosions on the gv and absence of other bleeding sources. * hemodynamically stable patient (mean arterial pressure above 65 mmhg) without clinical significant rebleeding (baveno criteria) within 12 hours after the initial endoscopy with glue obliteration. * written informed consent obtained. exclusion criteria: * pregnant woman or breastfeeding. * minor and patients older than 75 years. * non cirrhotic portal hypertension. * hepatocellular carcinoma outside the milan criteria or other cancer at a palliative stage. * child pugh score \> 13. * history of severe or refractory hepatic encephalopathy unrelated to gastrointestinal bleeding. * congestive heart failure. * history or presence of pulmonary hypertension. * patients with other indication for tips. * uncontrolled gastric variceal bleeding. * portal vein cavernoma. * patient who have previously received a tips procedure. * failure to receive clear information in patients without an identified trusted person. * refusal of the participation agreement by signing the information form and consent as defined. * exclusion period from another biomedical study.

Keywords: bleeding gastric varices cirrhosis type 2 gastro-esophageal varices isolated gastric varices transjugular intra-hepatic porto systemic shunt (tips) portal hypertension glue obliteration tissue adhesive
study to test use of a decision aid in a clinical visit to help patients choose a diabetes medication

Conditions: Type 2 Diabetes Mellitus

Summary: the goal of this study is to test the relative merits of a decision aid for diabetes medications that we have developed - diabetes medication choice cards- versus usual care in translating comparative effectiveness research (cer) into real world clinics. this study will involve about 20 primary care practice sites affiliated with mayo health system, park nicollet, or hennepin county medical center. there will be no recruiting done at the mayo clinic.

to conduct a cluster-randomized practical trial to evaluate the impact of our decision aid (diabetes medication choice cards) versus usual care as strategies to translate cer into practice among patients with poorly controlled diabetes in need of drug intensification (hemoglobin alc (hba1c) \> 7.3%). patient outcomes including reaching glycemic control target (hba1c less than or equal to 7.3%), medication choice and adherence, satisfaction and knowledge. from the physician perspective, we will be measuring physician adoption and satisfaction with the decision aid. to identify, describe, and explain factors that promote or inhibit the uptake of complex interventions such as decision aids in practices participating in the trial. to conduct an exploratory analysis of the ability of patients to adhere to the medications chosen while exploring the factors that enable or hinder the patients' ability to incorporate these medications into their routine.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * have a diagnosis of type 2 diabetes mellitus and on diabetes medication * have a diagnosis of type 2 diabetes mellitus for 1 year or more if not currently on diabetes medication * recognize their primary care provider as their main diabetes care provider * use 0, 1, 2, or 3 oral hypoglycemic agents * have a recent hba1c measure (within 12 months) of greater than 7.3, with priority to patients with rising hba1c levels. exclusion criteria: * not available for follow-up for 12 months after study visit. * unable to read and speak english. * has major barriers to providing written informed consent.

Keywords: decision aids shared medical decision making patient education endocrine system diseases glucose metabolism disorders metabolic diseases
pertuzumab in platinum-resistant low human epidermal growth factor receptor 3 (her3) messenger ribonucleic acid (mrna) epithelial ovarian cancer (penelope)

Conditions: Ovarian Cancer

Summary: this two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer. in the non-randomized part 1 safety run-in, participants will receive pertuzumab plus either topotecan or paclitaxel. in the randomized, double-blind part 2 of the study, participants will receive either pertuzumab or placebo in combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed epithelial ovarian, primary peritoneal, and/or fallopian tube cancer that is platinum-resistant or refractory * low human epidermal growth factor receptor (her) 3 messenger ribonucleic acid (mrna) expression * at least one measurable and/or non-measurable lesion according to response evaluation criteria in solid tumors (recist) version (v) 1.1 * eastern cooperative oncology group (ecog) performance status 0 to 2 * left ventricular ejection fraction (lvef) greater than or equal to (\>/=) 50 percent (%) * negative serum pregnancy test in women of childbearing potential * women of childbearing potential must agree to use effective contraception as defined by protocol during and for at least 6 months post study treatment exclusion criteria: * non-epithelial tumors * ovarian tumors with low malignant potential (borderline tumors) * history of other malignancy of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast * previous treatment with more than 2 chemotherapy regimens * any prior radiotherapy to the pelvis or abdomen * history or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy * pre-existing peripheral neuropathy \>/= common toxicity criteria (ctc) grade 2 (applicable for paclitaxel cohort only) * inadequate organ function * uncontrolled hypertension or clinically significant cardiovascular disease * current known infection with human immunodeficiency virus (hiv) or active infection with hepatitis b virus (hbv), or hepatitis c virus (hcv) * current chronic daily treatment with corticosteroids (\>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids * history of receiving any investigational treatment within 28 days prior to first study drug administration * for part 2 of the trial: prior enrollment into part 1 of the trial * concurrent participation in any therapeutic clinical trial
a study of a novel insulin lispro formulation in participants with type 1 diabetes mellitus using insulin pumps

Conditions: Diabetes Mellitus, Type 1

Summary: this study evaluates a new test formulation of a glucose lowering drug, insulin lispro, delivered by an insulin pump continuously under the skin. the study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes the new test formulation and its effect on blood sugar levels when it is delivered via an insulin pump. side effects and tolerability will be documented. the study will last about 4 to 11 weeks, including screening, lead-in and follow up. screening is required within 28 days prior to entering the study.


Eligibility criteria:
inclusion criteria: * male or female participants with type 1 diabetes mellitus (t1dm) who are receiving insulin therapy via an approved insulin pump * have a body mass index (bmi) of 18.5 to 33 kilogram per square meter (kg/m²), inclusive, at screening * have blood pressure, pulse rate, electrocardiogram (ecg), blood and urine laboratory test results that are acceptable for the study * have had no episodes of severe hypoglycemia in the past 6 months (requiring assistance in treatment by a second party) * have venous access sufficient to allow for blood sampling * have provided written consent and are willing to follow study procedures and commit to the study duration exclusion criteria: * are currently participating in or completed a clinical trial within the last 30 days from a clinical trial or any other type of medical research judged to be incompatible with this study * have previously participated or withdrawn from this study * have or used to have health problems, laboratory test results, blood pressure or ecg readings that, in the opinion of the doctor, could make it unsafe to participate in the study * had blood loss of more than 500 milliliters (ml) within the last month
assertive community treatment for patients suffering from substance use disorders

Conditions: Substance Use Disorders

Summary: according to the world health organization the population suffering from addiction problems is increasing. this population is characterized by multiple needs at the medico-psychosocial level. however, some of these patients, a particular subgroup that we are going to be interested in the so-called "high need" user group, find it difficult to access and stay in outpatient treatment programs. persons with substance use disorder often present a chaotic use of the health system, including a high number of hospitalizations in times of crisis. these individuals also show very low utilization of health care services, accompanied by social marginalization. this can be related to relapses and poor social functioning. a high number of relapses occur particularly at the end of hospitalization. community interventions, such as assertive community treatment (act) should increase the adherence of these patients to treatment by accompanying them in the community and helping them during sensitive and crisis periods. one of the objectives of the study is to evaluate the impact of act on the time until service disengagement, measuring treatment adherence. the secondary objectives of this study will be to see the effect of act on duration and type of hospitalizations, as well as the number of emergency room visits. the investigators will focus on the impact of act on the participant's medico-psycho-social network, substance use and other psychological variables. the investigators will also evaluate his or her psychiatric symptoms and global and social functioning. life satisfaction and satisfaction with the care received will also be measured. the study will investigate this through questionnaires at the beginning of care, at three months, six months and 12 months after the start of the act intervention.


Eligibility criteria:
inclusion criteria: * substance use disorder * competent subjects, able to give informed consent * french speaking exclusion criteria: * evidence of organic brain disease or learning disability based on the chart review.

Keywords: substance use disorders assertive community treatment community treatment treatment engagement service use
association between prescription of antidepressants and delirium in the elderly : analysis from the world health organization global database

Conditions: Antidepressive Agents; Aged; Delirium

Summary: delirium is a frequent reason for hospitalisation of the elderly. associations between the prescription of some medicines and the risk of delirium have already been demonstrated. antidepressants are widely prescribed in the elderly because of the frequency of anxiety-depressive symptoms in this population, where there are high pharmacokinetic and pharmacodynamic variability. however, the association between antidepressants and the risk of delirium remains poorly understood. based on the analysis from the world health organization global database, the main objective of this study is to investigate the association between the different classes of antidepressants and the occurrence of the " delirium " event reported in the database. a disproportionality analysis will be performed. it will aim to assess whether some classes of antidepressants, and within these classes some molecules, are associated with a greater risk of delirium.


Eligibility criteria:
inclusion criteria: * be over 65 years old * taking antidepressants * to have presented delirium exclusion criteria: -
a safety and efficacy study of vitreosolve® for non-proliferative diabetic retinopathy subjects

Conditions: Diabetic Retinopathy

Summary: the purpose of this study is to determine the safety and efficacy of vitreosolve® in diabetic retinopathy patients.


Eligibility criteria:
inclusion criteria: * subjects with a history of systemic diabetes(type i,or ii) * subject with a documented history of non- proliferative diabetic retinopathy(npdr) * subjects with no or partial pvd at baseline exam in study eye. exclusion criteria: * subjects with retinal pathology in the study eye other then (npdr) * subjects with high myopia in the study eye * subjects who have monocular vision or central lateral vision of 20/200 or worse bcva in the non-study eye. * subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less then 6 months prior to study enrollment. * subjects that have either vitrectomy surgery, intavitreal injections, or laser treatments in the study eye.

Keywords: diabetic retinopathy